Loading...
Docoh

Mannkind (MNKD)

News

From Benzinga Pro
MannKind Highlights FDA Approval Of United Therapeutics' Tyvaso DPI, Which Utilizes Technosphere Inhalation Platform
24 May 22
Biotech, News, FDA, General
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients
UPDATE: FDA Doc For United Therapeutics, MannKind Lung Disease Therapy (Link In Body Of This Headline)
23 May 22
Biotech, News, FDA, General
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214324s000lbl.pdf
'United Therapeutics, MannKind gain as FDA approve lung disease therapy' - Seeking Alpha Blog Post From Contributor
23 May 22
News, FDA
https://www.stockilluminati.com/mnkd/display.php?url=https%3a%2f%2fseekingalpha.com%2fnews%2f3841862-uthr-stock-mnkd-stock-gain-as-fda-approve-lung-disease-therapy%3futm_source%3dfeed_news_all%26utm_medium%3dreferral
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
17 May 22
Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Small Cap, FDA, Legal, Management, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Zealand Pharma Reports Deal To Sell Its V-Go Insulin Delivery Device To MannKind For $10M Plus Added Sales-Based Milestones
17 May 22
M&A, News, Asset Sales
Deal includes $10 million USD upfront payment to Zealand and sales-based milestones Certain inventory related to V-Go® and employees also included under the terms of the deal Agreement is part of Zealand’s
MannKind Q1 EPS $(0.10), Inline, Sales $11.99M Beat $10.58M Estimate
5 May 22
Earnings, News
MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 100 percent decrease over losses of $(0.05) per share from the same period last year. The company
Earnings Scheduled For May 5, 2022
5 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
MannKind Earnings Preview
4 May 22
Earnings
MannKind (NASDAQ:MNKD) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that MannKind will report an earnings per share (EPS) of $-0.10.
MannKind Announced Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30
27 Apr 22
News, Penny Stocks, Small Cap, Events
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has presented a poster [Abstract #445] at the 15th International Conference on Advanced Technologies & Treatments for Dia

Press releases

From Benzinga Pro
Mannkind to Host Product Theater and Booth at the American Diabetes Association's 82nd Scientific Sessions in New Orleans, June 3-7
3 Jun 22
News, Press Releases
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine
MannKind's Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
24 May 22
Health Care, Press Releases
Tyvaso DPI represents the second FDA-approved product utilizing MannKind's Technosphere® inhalation technologyFirst approval of a dry powder inhaled treatment for PAH and PH-ILDManufacturing of Tyvaso DPI for United
MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
19 May 22
News, Press Releases
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
17 May 22
Health Care, Press Releases, General
The once-daily insulin delivery device strengthens MannKind's commitment to offering innovative mealtime diabetes solutions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind
Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device
17 May 22
Press Releases
Company announcement – No. 21 / 2022 Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device Deal includes $10 million USD upfront payment to Zealand and
MannKind Corporation Participating at Upcoming Conferences
9 May 22
News, Press Releases
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients
MannKind Corporation Reports 2022 First Quarter Financial Results
5 May 22
Earnings, Press Releases
1Q 2022 Afrezza Net Revenue of $9.8 million; +21% vs. 1Q 20211Q 2022 Afrezza Gross Margin 77%; Gross Profit +99% vs 1Q 2021$233.0 million of Cash, Cash Equivalents, and Investments at March 31, 2022Tyvaso DPI PDUFA date
MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30
27 Apr 22
News, Press Releases
Simplified 2x dose of Technosphere® Insulin (TI) produced a statistically significant improvement in PPGE between Dose 1 & 2 from 45-120 minutesHigher dose of TI resulted in a mean difference of 52 mg/dL in PPGE